The Organization and Financing of End-stage Renal Disease Treatment in Japan

Overview

Journal Int J Health Care Finance Econ

Publisher Springer

Specialty Public Health

Date 2007 Aug 11

PMID 17690980

Citations 14

Authors

Shunichi Fukuhara

Chikao Yamazaki

Yasuaki Hayashino

Takahiro Higashi

Margaret A Eichleay

Takashi Akiba

Tadao Akizawa

Akira Saito

Friedrich K Port

Kiyoshi Kurokawa

Affiliations

Soon will be listed here.

Abstract

End-stage renal disease (ESRD) affects 230,000 Japanese, with about 36,000 cases diagnosed each year. Recent increases in ESRD incidence are attributed mainly to increases in diabetes and a rapidly aging population. Renal transplantation is rare in Japan. In private dialysis clinics, the majority of treatment costs are paid as fixed fees per session and the rest are fee for service. Payments for hospital-based dialysis are either fee-for-service or diagnosis-related. Dialysis is widely available, but reimbursement rates have recently been reduced. Clinical outcomes of dialysis are better in Japan than in other countries, but this may change given recent ESRD cost containment policies.

Citing Articles

Cost-Effectiveness of Empagliflozin in CKD with or without Albuminuria.

Odawara M, Nishi H, Kodera S, Kondo M, Nangaku M Clin J Am Soc Nephrol. 2025; 20(1):50-61.

PMID: 39792538 PMC: 11737442. DOI: 10.2215/CJN.0000000582.

The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients.

Konta T, Asahi K, Tamura K, Tanaka F, Fukui A, Nakamura Y Clin Exp Nephrol. 2024; .

PMID: 39676148 DOI: 10.1007/s10157-024-02600-9.

The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes.

Asahi K, Konta T, Tamura K, Tanaka F, Fukui A, Nakamura Y J Diabetes Investig. 2024; 16(1):108-119.

PMID: 39576736 PMC: 11693570. DOI: 10.1111/jdi.14293.

Questionnaire survey of the frequency of dietary intake during hemodialysis and the impact of COVID-19 in Japan.

Kabasawa H, Hosojima M, Narita I Clin Exp Nephrol. 2023; 28(3):254-260.

PMID: 37982979 DOI: 10.1007/s10157-023-02430-1.

Payment systems for dialysis and their effects: a scoping review.

Emrani Z, Amiresmaili M, Daroudi R, Najafi M, Akbari Sari A BMC Health Serv Res. 2023; 23(1):45.

PMID: 36650516 PMC: 9847119. DOI: 10.1186/s12913-022-08974-4.

References

. An overview of regular dialysis treatment in Japan as of 31 December 2003. Ther Apher Dial. 2005; 9(6):431-58. DOI: 10.1111/j.1744-9987.2005.00328.x. View

Iglehart J . Japan's medical care system--Part Two. N Engl J Med. 1988; 319(17):1166-72. DOI: 10.1056/nejm198810273191731. View

Hirth R . The organization and financing of kidney dialysis and transplant care in the United States of America. Int J Health Care Finance Econ. 2007; 7(4):301-18. DOI: 10.1007/s10754-007-9019-6. View

OLIVER A, IKEGAMI N, Ikeda S . Japan's aging population. Implications for healthcare. Pharmacoeconomics. 1997; 11(4):306-18. DOI: 10.2165/00019053-199711040-00002. View

Pisoni R, Bragg-Gresham J, Young E, Akizawa T, Asano Y, Locatelli F . Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44(1):94-111. DOI: 10.1053/j.ajkd.2004.03.023. View

Fukuhara S, Green J, Takai I, Shinzato T, Uchida K, Oshima S . Health-related quality of life among renal-transplant recipients in Japan. Transplantation. 1999; 68(9):1331-5. DOI: 10.1097/00007890-199911150-00019. View

IKEGAMI N . Japanese health care: low cost through regulated fees. Health Aff (Millwood). 1991; 10(3):87-109. DOI: 10.1377/hlthaff.10.3.87. View

Asai A, Fukuhara S, Lo B . Attitudes of Japanese and Japanese-American physicians towards life-sustaining treatment. Lancet. 1995; 346(8971):356-9. DOI: 10.1016/s0140-6736(95)92230-x. View

IKEGAMI N, Campbell J . Medical care in Japan. N Engl J Med. 1995; 333(19):1295-9. DOI: 10.1056/NEJM199511093331922. View

10.

Hidai H . Need for an incentive-based reimbursement policy toward quality care for dialysis patient management. Kidney Int. 2000; 58(1):363-73. DOI: 10.1046/j.1523-1755.2000.00174.x. View

11.

Nakai S, Shinzato T, Nagura Y, Masakane I, Kitaoka T, Shinoda T . An overview of regular dialysis treatment in Japan (as of 31 December 2001). Ther Apher Dial. 2004; 8(1):3-32. DOI: 10.1111/j.1526-0968.2004.00109.x. View

12.

Fukuhara S, Lopes A, Bragg-Gresham J, Kurokawa K, Mapes D, Akizawa T . Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2003; 64(5):1903-10. DOI: 10.1046/j.1523-1755.2003.00289.x. View

13.

Saran R, Bragg-Gresham J, Levin N, Twardowski Z, Wizemann V, Saito A . Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int. 2006; 69(7):1222-8. DOI: 10.1038/sj.ki.5000186. View

14.

Dor A, Pauly M, Eichleay M, Held P . End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ. 2007; 7(2-3):73-111. DOI: 10.1007/s10754-007-9024-9. View

15.

Lee H, Manns B, Taub K, Ghali W, Dean S, Johnson D . Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002; 40(3):611-22. DOI: 10.1053/ajkd.2002.34924. View